Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25643875 | 1.00 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9ALDH1A1CDK2 | |
| SCHEMBL25228399 | 1.00 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9ALDH1A1CDK2 | |
| SCHEMBL25642286 | 1.00 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9ALDH1A1CDK2 | |
| SCHEMBL25223204 | 1.00 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9ALDH1A1CDK2 | |
| SCHEMBL25642250 | 1.00 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9ALDH1A1CDK2 | |
| SCHEMBL19834836 | 0.95 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25270490 | 0.91 | NAMPT (0.50) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL25261307 | 0.91 | NAMPT (0.50) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL25642158 | 0.91 | NAMPT (0.50) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL25642275 | 0.91 | NAMPT (0.50) | NAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091385-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-09-17 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP3A4 2944/4885CYP2C9 1650/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885CYP3A4 2815/4885CYP2C9 1456/4885 |
| US-12091385-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885CYP3A4 2815/4885CYP2C9 1456/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885CYP3A4 2815/4885CYP2C9 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.